open access

Vol 55, No 1 (2021)
Invited Review Article
Published online: 2021-02-08
Submitted: 2021-01-18
Accepted: 2021-01-25
Get Citation

COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society

Monika Nojszewska, Alicja Kalinowska, Monika Adamczyk-Sowa, Alina Kułakowska, Halina Bartosik-Psujek
DOI: 10.5603/PJNNS.a2021.0016
·
Pubmed: 33555604
·
Neurol Neurochir Pol 2021;55(1):8-11.

open access

Vol 55, No 1 (2021)
Invited review articles
Published online: 2021-02-08
Submitted: 2021-01-18
Accepted: 2021-01-25

Abstract

A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society has developed a statement with regard to the currently available mRNA vaccines (Pfizer-BioNTech and Moderna) preventing novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) infection, which causes Coronavirus disease 2019 (COVID-19), in patients with multiple sclerosis (MS). This statement has been based on the literature available as of 15 January, 2021. The guidance will be updated as new data emerges. All data regarding the above-mentioned vaccines comes from clinical trials which have been reviewed, published and approved by the regulatory authorities [1, 2]. In the current manuscript, whenever a SARS-CoV-2 vaccine is discussed, it refers to mRNA vaccines only.

Abstract

A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society has developed a statement with regard to the currently available mRNA vaccines (Pfizer-BioNTech and Moderna) preventing novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) infection, which causes Coronavirus disease 2019 (COVID-19), in patients with multiple sclerosis (MS). This statement has been based on the literature available as of 15 January, 2021. The guidance will be updated as new data emerges. All data regarding the above-mentioned vaccines comes from clinical trials which have been reviewed, published and approved by the regulatory authorities [1, 2]. In the current manuscript, whenever a SARS-CoV-2 vaccine is discussed, it refers to mRNA vaccines only.

Get Citation

Keywords

multiple sclerosis, COVID-19, vaccines, SARS-CoV-2, guidelines

About this article
Title

COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 1 (2021)

Article type

Invited Review Article

Pages

8-11

Published online

2021-02-08

DOI

10.5603/PJNNS.a2021.0016

Pubmed

33555604

Bibliographic record

Neurol Neurochir Pol 2021;55(1):8-11.

Keywords

multiple sclerosis
COVID-19
vaccines
SARS-CoV-2
guidelines

Authors

Monika Nojszewska
Alicja Kalinowska
Monika Adamczyk-Sowa
Alina Kułakowska
Halina Bartosik-Psujek

References (27)
  1. Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
  2. Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020 [Epub ahead of print].
  3. Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019; 93(13): 584–594.
  4. Lebrun C, Vukusic S. French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SFSEP). Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Mult Scler Relat Disord. 2019; 31: 173–188.
  5. Loebermann M, Winkelmann A, Hartung HP, et al. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol. 2012; 8(3): 143–151.
  6. Riva A, Barcella V, Benatti SV, et al. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Mult Scler. 2020 [Epub ahead of print]: 1352458520952310.
  7. Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020; 45: 102439.
  8. Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020; 95(14): e1999–e2008.
  9. Pellegrino P, Carnovale C, Perrone V, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. Vaccine. 2014; 32(37): 4730–4735.
  10. Wiedermann U, Sitte H, Burgmann H, et al. Impfungen bei Immundefekten/Immunsuppression – Expertenstatement und Empfehlungen. Wiener klinische Wochenschrift. 2016; 128(S4): 337–376.
  11. Zrzavy T, Kollaritsch H, Rommer PS, et al. Vaccination in Multiple Sclerosis: Friend or Foe? Front Immunol. 2019; 10: 1883.
  12. Reyes S, Ramsay M, Ladhani S, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020; 20(6): 435–445.
  13. Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011; 258(7): 1197–1206.
  14. Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol. 2017; 264(6): 1035–1050.
  15. Moiola L, Barcella V, Benatti S, et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Mult Scler. 2020 [Epub ahead of print]: 1352458520952311.
  16. Waldman RA, Creed M, Sharp K, et al. Letter in Reply: Toward a COVID-19 Vaccine Strategy for Pemphigus Patients on Rituximab. J Am Acad Dermatol. 2020 [Epub ahead of print].
  17. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public (16 Jan 2021).
  18. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf (16 Jan 2021).
  19. https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-product-information_en.pdf (16 Jan 2021).
  20. Morales FS, Koralnik IJ, Gautam S, et al. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. J Neurol. 2020; 267(1): 125–131.
  21. Zheng C, Kar I, Chen CK, et al. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020; 34(9): 879–896.
  22. Barry B, Erwin AA, Stevens J, et al. Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations. Neurol Ther. 2019; 8(2): 241–250.
  23. https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_en.pdf (16 Jan 2021).
  24. https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf (16 Jan 2021).
  25. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020; 43: 102195.
  26. Mycko MP. B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection? Neurol Neurochir Pol. 2020; 54(6): 490–501.
  27. McCarthy CL, Tuohy O, Compston DA, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013; 81(10): 872–876.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl